摘要
目的:研究微小RNA(miR)-153是否靶向正性调控域锌指蛋白2(PRDM2)基因并通过调控JAK/STAT信号通路影响膀胱癌细胞的侵袭和迁移。方法:运用q PCR检测miR-153在膀胱癌组织中的表达;运用免疫组化检测PRDM2在正常组织和膀胱癌组织中的表达;Western blot检测不同膀胱癌细胞株中PRDM2的表达情况;双萤光素酶报告基因系统检测miR-153对PRDM2转录活性的影响;Transwell侵袭实验检测miR-153过表达对膀胱癌细胞RT4侵袭能力的影响;划痕实验检测miR-153过表达对膀胱癌细胞RT4迁移能力的影响;Western blot实验检测过表达miR-153后JAK/STAT信号通路蛋白的水平。结果:和正常组织比较,PRDM2蛋白在膀胱癌中表达较高(P<0.05);miR-153的表达水平在膀胱癌组织中较低(P<0.05);双荧光素酶报告基因系统检测结果显示,miR-153可以调控PRDM2的表达水平;过表达miR-153后,膀胱癌细胞株RT4的侵袭和迁移能力明显降低,p-JAK2和p-STAT3的蛋白水平下调。结论:miR-153靶向PRDM2,并通过JAK/STAT信号通路调控膀胱癌细胞的侵袭和迁移能力。
AIM:To investigate the effect of microRNA(miR)-153-targeted positive regulatory domain zinc finger protein2(PRDM2)on invasion and migration abilities of bladder cancer cells through JAK/STAT signaling pathway.METHODS:The expression levels of miR-153in bladder cancer tissues were detected by qPCR.The expression of PRDM2in normal tissues and bladder cancer tissues was detected by immunohistochemistry.The effect of miR-153on the transcriptional activity of PRDM2was examined by dual-luciferase reporter assay system.The effect of miR-153over-expression on the invasion ability of bladder cancer RT4cells was detected by Transwell assay,and the cell invasion ability was analyzed by scratch test.The protein levels of PRDM2,p-JAK2and p-STAT3were determined by Western blot.RESULTS:The expression of miR-153was significantly lower in the bladder cancer tissues than that in normal tissues(P<0.05).PRDM2was highly expressed in the bladder cancer tissue(P<0.05).The results of dual-luciferase reporter assay system showed that miR-153regulated the expression of PRDM2.miR-153over-expression significantly decreased the invasion and migration abilities of bladder cancer RT4cells.miR-153over-expression also down-regulated the protein levels of p-JAK2and p-STAT3(P<0.05).CONCLUSION:miR-153targets PRDM2,and regulates the invasion and migration abilities of bladder cancer cells by JAK/STAT signaling pathway.
作者
李冠军
亚国伟
唐正严
苏开德
LI Guanjun;YA Guowei;TANG Zhengyan;SU Kaide(Department of Urology,The First Affiliated Hospital of Nanyang Medical College, Nanyang 473000,China;Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang 473000,China;Department of Urology, Xiangya Hospital, Central South University, Changsha 410008 , China;Department of Urology, Changde First People’s Hospital, Changde 415003 , China)
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2018年第1期58-63,共6页
Chinese Journal of Pathophysiology
基金
河南省医学科技攻关计划(No.2011020091)
